ADMA vs RXRX: stock comparison and AI forecast
Adma Biologics, Inc. (ADMA) and Recursion Pharmaceuticals, Inc. (RXRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ADMA Adma Biologics, Inc.
- Market Cap
- $2.48B
- P/E Ratio
- 17.8x
- Size
- mid-cap
- AI Forecast
RXRX Recursion Pharmaceuticals, Inc.
- Price
- $3.83 +8.8% · 6M
- Market Cap
- $2.29B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ADMA and RXRX have similar market capitalizations ($2.48B and $2.29B).
- ADMA turns 33.0% of its revenue into net income, against -879.4% for RXRX.
- ADMA carries 0.68 times debt per unit of equity, against 0.35 times for RXRX.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ADMA | RXRX |
|---|---|---|
| Market Cap | $2.48B | $2.29B |
| P/E Ratio | 17.84x | – |
| P/B Ratio | 6.07x | 2.53x |
| EPS | $0.62 | $-1.30 |
| Book Value/Share | $1.82 | $1.51 |
| Revenue/Share | $2.29 | $0.09 |
| FCF/Share | $0.52 | $-0.52 |
Profitability & Margins
| Metric | ADMA | RXRX |
|---|---|---|
| ROE | 41.4% | -52.5% |
| ROA | 24.7% | -38.9% |
| ROIC | 36.9% | -45.0% |
| Gross Margin | 64.7% | – |
| Operating Margin | 43.8% | -915.1% |
| Net Margin | 33.0% | -879.4% |
| EBT Margin | 42.3% | -887.8% |
| Tax Rate | 21.9% | 0.9% |
Financial Health
| Metric | ADMA | RXRX |
|---|---|---|
| Current Ratio | 6.97x | 5.01x |
| Quick Ratio | 3.81x | – |
| D/E Ratio | 0.68x | 0.35x |
| Financial Leverage | 1.68x | 1.35x |
| Interest Coverage | 13.6x | -4817.0x |
| Working Capital | $452M | $493M |
Cash Flow
| Metric | ADMA | RXRX |
|---|---|---|
| Operating Cash Flow | $137M | -$311M |
| Free Cash Flow | $116M | -$312M |
| Capital Spending | -$20M | -$2M |
| OCF Growth YoY | 78.2% | – |
| FCF Growth YoY | 77.1% | – |
| FCF/Sales | 22.7% | -577.7% |
| CapEx/Sales | 4.0% | 3.6% |
Operational Efficiency
| Metric | ADMA | RXRX |
|---|---|---|
| Asset Turnover | 0.75x | 0.04x |
| Receivables Turnover | 3.7x | – |
| Inventory Turnover | 0.8x | – |
| Fixed Assets Turnover | 7.7x | 0.6x |
| Days Sales Outstanding | 98 days | – |
| Days Inventory | 483 days | – |
| Payables Period | 64 days | 124 days |
| Cash Conversion Cycle | 518 days | – |
Income Statement
| Metric | ADMA | RXRX |
|---|---|---|
| Total Revenue | $512M | $54M |
| Operating Income | $224M | -$495M |
| Net Income | $169M | -$476M |
| R&D Expense | $12M | $373M |
| SG&A Expense | $99M | – |
| Cost of Goods Sold | $181M | $48M |
Dividend & Shareholder Information
| Metric | ADMA | RXRX |
|---|---|---|
| Shares Outstanding | 224M | 598M |
| Net Income Growth | -19.1% | – |
| EPS Growth | -24.4% | – |
ADMA vs RXRX: stock comparison and AI forecast
Which is bigger, ADMA or RXRX?
ADMA and RXRX have similar market capitalizations ($2.48B and $2.29B).
Which one does Intratio's AI model rank higher, ADMA or RXRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.